As for trastuzumab, one variant within the FCGR2A gene (rs1801274-G), which is associated with decreased efficacy (LOE 2B), and one variant within the ERBB2 gene, which is implicated in cardiomyopathy development (LOE 3), were underrepresented in FVG population suggesting an higher therapeutic...
Moreover, the need for chronic oxygen supplementation was recorded both for baseline and for the time of the follow-up visit. The presence of main chronic diseases, including heart disease (heart failure, ischemic cardiomyopathy), hypertension, diabetes mellitus, chronic renal disease, pulmonary ...